Chloroethylnorapomorphine

Chloroethylnorapomorphine
Names
	IUPAC name 6-(2-Chloro-ethyl)-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
	Other names (−)-N-(2-Chloroethyl)-norapomorphine
Identifiers
CAS Number	75946-94-0 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL283871 ;
ChemSpider	137707 ;
PubChem CID	156376;
CompTox Dashboard (EPA)	DTXSID90226853 ;
	InChI InChI=1S/C18H18ClNO2/c19-7-9-20-8-6-11-2-1-3-13-16(11)14(20)10-12-4-5-15(21)18(22)17(12)13/h1-5,14,21-22H,6-10H2/t14-/m1/s1 Key: RMKWDBUEXHJPRZ-CQSZACIVSA-N ;
	SMILES C1CN([C@@H]2CC3=C(C4=C2C1=CC=C4)C(=C(C=C3)O)O)CCCl;
Properties
Chemical formula	C18H18ClNO2
Molar mass	315.80 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Chloroethylnorapomorphine is a chemical once thought to be an irreversible dopamine D₂ receptor antagonist;^[1]^[2] however, it was later proved to be reversible.^[3]

References

^ Cohen, SA; Neumeyer, JL. (Oct 1983). "Kinetics of solvolysis of N-(2-chloroethyl)norapomorphine, an irreversible dopamine receptor antagonist". Journal of Medicinal Chemistry. 26 (10): 1348–53. doi:10.1021/jm00364a003. PMID 6620296. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Guan, JH; Neumeyer, JL; Filer, CN; Ahern, DG; Lilly, L; Watanabe, M; Grigoriadis, D; Seeman, P. (Jun 1984). "N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application". Journal of Medicinal Chemistry. 27 (6): 806–10. doi:10.1021/jm00372a019. PMID 6737423. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Lehmann, J; Langer, SZ (1982). "Dopamine autoreceptors differ pharmacologically from postsynaptic dopamine receptors: Effects of (−)-N-(2-chloroethyl)-norapomorphine". European Journal of Pharmacology. 77 (1): 85–6. doi:10.1016/0014-2999(82)90542-8. PMID 7060630.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Cohen, SA; Neumeyer, JL. (Oct 1983). "Kinetics of solvolysis of N-(2-chloroethyl)norapomorphine, an irreversible dopamine receptor antagonist". Journal of Medicinal Chemistry. 26 (10): 1348–53. doi:10.1021/jm00364a003. PMID 6620296. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[2] Guan, JH; Neumeyer, JL; Filer, CN; Ahern, DG; Lilly, L; Watanabe, M; Grigoriadis, D; Seeman, P. (Jun 1984). "N-(2-chloroethyl) [8,9-2H]norapomorphine, an irreversible ligand for dopamine receptors: synthesis and application". Journal of Medicinal Chemistry. 27 (6): 806–10. doi:10.1021/jm00372a019. PMID 6737423. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[3] Lehmann, J; Langer, SZ (1982). "Dopamine autoreceptors differ pharmacologically from postsynaptic dopamine receptors: Effects of (−)-N-(2-chloroethyl)-norapomorphine". European Journal of Pharmacology. 77 (1): 85–6. doi:10.1016/0014-2999(82)90542-8. PMID 7060630.

[1]

[2]

[3]